The Impact and Effectiveness of a Two-Dose Varicella Immunization Program Among School Children: Evidence from Quasi-experimental Analyses

Infectious Diseases and Therapy, 2026

Полный текст Открытый доступ: Gold Метаданные (CSL-JSON)
DOI 10.1007/s40121-026-01331-6
Достоверность данных 70 средняя
Как считается эта оценка

Складывается из проверяемых признаков самой записи: есть ли у статьи DOI, сколько независимых источников подтвердили её данные, заполнены ли обязательные поля и насколько свежо последнее подтверждение. Снижают оценку расхождения между источниками и отсутствие идентификатора. Значение от 80 означает, что запись опубликована без дополнительной проверки; от 60 до 79 — что она опубликована с пониженной достоверностью и ручная проверка желательна. Запись, выверенную редактором вручную, пересчёт не опускает ниже 90. Это оценка наших данных о статье, а не оценка самой статьи.

Аннотация

INTRODUCTION: Varicella, caused by the varicella zoster virus, poses a significant public health challenge, particularly among children. To address this, the city of Shenzhen, China, introduced a publicly funded vaccination program offering free two-dose varicella vaccines to eligible school-aged cohorts. This study aims to evaluate the program's impact on disease incidence, vaccination uptake, and the comparative effectiveness of two-dose versus single-dose regimens. METHODS: We used the individual-level data from official immunization and surveillance systems, covering pupils born between 1 September 2014 and 31 August 2015. Applying a difference-in-differences approach, we compared the disease incidence and vaccination uptake between the eligible cohort and ineligible cohort. Additionally, to further evaluate the effectiveness of the two-dose vaccination schedule, we implemented a regression discontinuity design using the policy cutoff date. RESULT: The policy reduced varicella incidence by 22.96% (95% CI 8.98-34.79%, p < 0.05) in the eligible cohort relative to the ineligible one, while boosting first- and second-dose coverage by 34.97% (95% CI 28.19-2.11%, p < 0.05) and 98.05% (95% CI 91.98-104.31%, p < 0.05), respectively. The regression discontinuity design indicated that the two-dose schedule conferred 75.19% (95% CI 70.62-79.06%) relative vaccine effectiveness against breakthrough varicella after a single dose. This study's main limitation is that, while reporting of varicella cases is mandatory, underreporting and misdiagnosis remain possible, potentially underestimating true incidence. CONCLUSIONS: These findings demonstrate the program's success in reducing disease burden and enhancing immunization rates, underscoring the superior protection of two-dose vaccination and providing strong evidence for policymakers to expand such initiatives.